Abstract CT233: Initial Results of a Phase 1b/2 Study of ADG126 (a Masked Anti-Ctla-4 SAFEbody®) in Combination with Pembrolizumab (an Anti-Pd-1 Antibody) in Patients with Advanced/metastatic Solid Tumors
Cancer Research（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要